Ann: Quarterly Activity Report & Appendix 4C - 30 June 2020, page-18

Fantastic transparent update, a few highlights:

- Revenues for FY20 in excess of $5 million and Cash of over $27 million. Further significant additional cash receipts from sales made during the quarter expected to be received this quarter.
- NG Biotech committing to the purchase of more than 1.75m devices during the quarter (an increase of 250K units)
- Discussions are well progressed for potential COVID-19 partnerships for distribution into other markets, including North America.
- Doubling of capacity to 500,000 units per month this quarter, on track to manufacture 1 million per month by the end of the year

The question is not of demand, its of supply and if they are able to achieve anywhere near 12 million units per quarter x assuming a $10 blended average cost per device would be significant revenue for Atomo and likely demanding a market cap well over $1.

I will be looking to add on any major weakness in the share price.